<?xml version="1.0" encoding="UTF-8"?>
<p id="para0029">In our study, the small number of cases with fatal outcomes precluded statistical comparisons of antibody titers of fatal cases 
 <italic>vs.</italic> nonfatal cases. For A(H7N9) virus-specific antibody responses in patients during hospitalization, Zhang et al. reported that neutralizing antibody titers increased faster in survivors than in fatal cases
 <xref rid="bib0034" ref-type="bibr">
  <sup>34</sup>
 </xref>; however, no statistically significant difference between antibody titers for fatal 
 <italic>vs.</italic> nonfatal cases was found in another patient cohort.
 <xref rid="bib0037" ref-type="bibr">
  <sup>37</sup>
 </xref> For A(H7N9) virus-specific antibody responses after discharge in survivors, Ma et al. found no association between disease severity and antibody response in one study,
 <xref rid="bib0020" ref-type="bibr">
  <sup>20</sup>
 </xref> while reported that severe disease was associated with higher HAI titer after discharge in another study.
 <xref rid="bib0021" ref-type="bibr">
  <sup>21</sup>
 </xref> Antibody responses to A(H5N1) virus infection after recovery have been reported to be lower in patients with asymptomatic infection than in those with severe illness.
 <xref rid="bib0030" ref-type="bibr">
  <sup>30</sup>
 </xref> Previous studies in A(H7N9) virus infected patients indicate that effective cross-reactive T cell memory is important for protection against severe influenza disease caused by newly emerging influenza A viruses.
 <xref rid="bib0038" ref-type="bibr">38</xref>, 
 <xref rid="bib0039" ref-type="bibr">39</xref>, 
 <xref rid="bib0040" ref-type="bibr">40</xref> Therefore, lack of sufficient T cell response might result in prolonged viral replication and cytokine dysregulation, more severe disease and higher antibody responses in most patients.
</p>
